For patients who are straightforward candidates, meaning no significant comorbidities, no psychiatric history, no prior GI disease, no eating disorder history, and no drug-drug interaction concerns, Mochi Health's model may be sufficient to deliver the clinical contact points the AACE recommends
Our apprehension is heightened, ironically, because recent studies have corroborated in children and adolescents the remarkable effectiveness of the GLP-1RAs in the management of type 2 diabetes and, as satiety-enhancing medications, in obesity that had been previously demonstrated in adults
If you are chronically sleep-deprived, your skin may suffer simply because your body hasn't had the time to "recharge" its antioxidant levels
Hydration matters enormously
Are other dual-agonists in development as effective, and what factors (e.g., tolerability profile) may allow for competitive differentiation
Eli Lilly is developing an investigational oral GLP-1 medication called orforglipron , but there is no approved tirzepatide pill at this time
